Latest News

Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting


SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting

Source link

Related posts

Biotech VC Bob Nelsen called it right on the coronavirus. Now he has thoughts on therapeutics — and masks

Newsemia

Nano-sized copper compounds together with immunotherapy can kill cancer cells

Newsemia

Peer relationship experiences of deaf and hard of hearing adolescents

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy